May 2008
Volume 49, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2008
Intravitreal Rapamycin and Bevacizumab Inhibits VEGF Expression in a Swine Model of Neovascularization
Author Affiliations & Notes
  • D. Moreno-Paramo
    Retina, APEC, Mexico, Mexico
  • R. Velez-Montoya
    Retina, APEC, Mexico, Mexico
  • J. Flores-Estrada
    Retina, APEC, Mexico, Mexico
  • A. Rodriguez-Reyes
    Retina, APEC, Mexico, Mexico
  • I. Hernandez-Ayuso
    Retina, APEC, Mexico, Mexico
  • E. Torres Porras
    Retina, APEC, Mexico, Mexico
  • E. Romo-Garcia
    Retina, APEC, Mexico, Mexico
  • A. Hitos-Fajer
    Retina, APEC, Mexico, Mexico
  • G. Garcia-Aguirre
    Retina, APEC, Mexico, Mexico
  • H. Quiroz-Mercado
    Retina, APEC, Mexico, Mexico
  • Footnotes
    Commercial Relationships  D. Moreno-Paramo, None; R. Velez-Montoya, None; J. Flores-Estrada, None; A. Rodriguez-Reyes, None; I. Hernandez-Ayuso, None; E. Torres Porras, None; E. Romo-Garcia, None; A. Hitos-Fajer, None; G. Garcia-Aguirre, None; H. Quiroz-Mercado, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2008, Vol.49, 3457. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      D. Moreno-Paramo, R. Velez-Montoya, J. Flores-Estrada, A. Rodriguez-Reyes, I. Hernandez-Ayuso, E. Torres Porras, E. Romo-Garcia, A. Hitos-Fajer, G. Garcia-Aguirre, H. Quiroz-Mercado; Intravitreal Rapamycin and Bevacizumab Inhibits VEGF Expression in a Swine Model of Neovascularization. Invest. Ophthalmol. Vis. Sci. 2008;49(13):3457. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To assess if the association of intravitreal rapamycin and bevacizumab have an additive effect in decreasing vitreous VEGF levels more than bevacizumab alone. To assess the safety of intravitreal rapamycin in a porcine model of choroidal neovascularization.

Methods: : We included eight eyes in the study. A choroidal neovascularization was created using argon laser shots. We divided the eyes in four groups: Group A (N=2) was injected with 1ml of intravitreal bevacizumab alone (2.25 mg/ml). Group B was injected with balanced saline solution, group C with 0.5ml of rapamycin (1mg/ml) and bevacizumab and group D just with rapamycin. The eyes were enucleated 21 days after the injections. We performed RT-PCR studies to all samples.

Results: : A decrease in VEGF expression in group A, C and D was observed. The most important reduction was observed in group A. No structural damage was detected in eyes injected with intravitreal rapamycin or bevacizumab.

Conclusions: : Intravitreal rapamcin is safe for intravitreal administration with no structural alterations. The combination of rapamycin and bevacizumab is not better than bevacizumab alone in decreasing VEGF vitreous levels.

Keywords: retinal neovascularization • retina • neovascularization 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×